Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences ... ( CRANBURY N.J. Sept. 17 /- Amicus ...)

Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference

Date:9/17/2008

CRANBURY, N.J., Sept. 17 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), today announced that President and Chief Executive Officer John F. Crowley will make a presentation at the UBS Global Life Sciences Conference on Wednesday, September 24, 2008, at 10:30 a.m. EDT in New York.

An audio webcast of the presentation will be available at the Amicus Web site at http://www.amicustherapeutics.com. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the webcast. An audio replay of the webcast will also be available on the Company's Web site for 30 days until October 24, 2008.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

FOLD-G

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:5/23/2013)... Pa. , May 23, 2013 ... research and advisory firms for specialized biopharmaceutical issues, ... hepatologists, and infectious disease specialists reported that in ... patients (e.g., intentionally delaying treatment) in anticipation of ... than six months ago, when only 6 percent ...

(Date:5/23/2013)... 2013 Northwest Biotherapeutics (NASDAQ: NWBO ... personalized immune therapies for solid tumor cancers, announced ... year,s American Society Of Clinical Oncology (ASCO) meeting in ... role in immune therapy. (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ... the pre-eminent conference focused on clinical treatment of cancer, ...

(Date:5/23/2013)... DIEGO , May 23, 2013 Verenium Corporation ... company focused on the development and commercialization of high-performance ... , Chief Financial Officer, will present at two upcoming ... Mr. Black will present at the Second Annual Marcum ... the Grand Hyatt Hotel in New York City. The ...

(Date:5/23/2013)... 2013 SynCardia Systems, Inc. ( http://www.syncardia.com ... Health Canada and CE (Europe) approved Total Artificial Heart, ... which boasts more than 380,000 visitors annually, is featuring ... by the Freedom® portable driver as part of its ... exhibitions of its kind. , “BodyWorks combines the ...

Breaking Biology Technology:The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2 The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3 NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2 NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3 Verenium To Present At Two Upcoming Conferences 2 Verenium To Present At Two Upcoming Conferences 3 SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2 SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3

[0] The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments [0] NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer [0] Verenium To Present At Two Upcoming Conferences [0] SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre

... (OTCQB: ILIU) today issued financial and operational results for ... December 31, 2010. "We made good ... with Stanford University, data from a clinical study was ... genetics has in improving weight loss. Our Inherent Health ...

... FRANCISCO, March 21, 2011 VentiRx Pharmaceuticals, Inc., ... novel Toll-Like Receptor 8 (TLR8) agonists and antagonists ... diseases, announced today the presentation of positive clinical ... VTX-1463 for the treatment of allergic rhinitis. The ...

... SAN CARLOS, Calif., March 21, 2011 WaferGen ... ), a leading developer of state-of-the-art genomic analysis ... innovative genomic samples preparation, today announced they will ... gene expression profiling and target enrichment to enable ...

Cached Biology Technology:Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 2 Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 3 Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 4 Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 5 Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 6 Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 7 VentiRx Pharmaceuticals Presents Positive Clinical and Pre-Clinical Data at American Academy of Allergy Asthma & Immunology Annual Meeting 2 WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing 2 WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing 3 WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing 4

Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results VentiRx Pharmaceuticals Presents Positive Clinical and Pre-Clinical Data at American Academy of Allergy Asthma & Immunology Annual Meeting WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing

(Date:5/22/2013)... 2013 U.S. Forest Service scientists are part of ... from the TKF Foundation, will examine how collaborative planning ... recover from tragedy. , The TKF Foundation announced today ... selected for grant funding. In addition to research on ... recovery and resiliency, the 3-year, $585,000 grant will contribute ...

(Date:5/22/2013)... technique that can detect molecular variants in chemical mixtures ... the most important, though time-consuming, processes in analytical chemistry. ... Nature , post-doctoral researcher David Patterson, Professor of Physics ... for Free-Electron Laser Science (CFEL) in Hamburg, Germany developed ... identify molecular variants apart, and to determine how much ...

(Date:5/22/2013)... genetic engineering drastically reduces the time and effort ... workhorses of biotechnology, scientists are reporting. Published in ... method paves the way for more rapid development ... and other activities. , Keith Shearwin and colleagues ... the genetic material DNA into a bacterium,s genome ...

Breaking Biology News(10 mins):'Landscapes of Resilience' to study how people use nature as a source of recovery 2 Detecting mirror molecules 2 Detecting mirror molecules 3

[0] 'Landscapes of Resilience' to study how people use nature as a source of recovery [0] Detecting mirror molecules [0] Fast new, 1-step genetic engineering technology

... Biochemist Glenn King is searching for an alternative to ... one the world's most efficient insect predators -- spiders. ... large Australian spider with a bite that is deadly ... of venom for King's research. The spider "cooperates" by ...

... B cell chronic lymphocytic leukemia (B-CLL),is the most ... the,progressive accumulation of mature B lymphocytes in the ... that in the early stages,of disease, B-CLL is ... signals that trigger normal B cell death (apoptosis). ...

... rapid advancement of biomedical science and the development ... types of information from biomedical text has become ... quite useful for interpreting large amounts of high-throughput ... information related to gene functions from text has ...

Cached Biology News:Spider Venom Could Yield Eco-Friendly Insecticides 2 Spider Venom Could Yield Eco-Friendly Insecticides 3

Spider Venom Could Yield Eco-Friendly Insecticides Enzyme allows B cells to resist death, leading to leukemia Automatic extraction of gene/protein biological functions from biomedical text

Peptide-affinity Purified Polyclonal Antibody to Purinergic Receptor P2Y12...

Purified anti-PXR...

Goat polyclonal to MLH3 Immunogen: Synthetic peptide: RQSLQQSMPPCEPP (Human) from C Terminus of the protein sequence according to NP_055196....

Purified anti-DNA-PKcs Phosphorylated (Thr2609)...

Biology Products:

Rabbit Anti-Human Purinergic Receptor P2Y12 Polyclonal Antibody, Unconjugated from IMGENEX Rabbit Anti-PXR (Poly6169) Polyclonal Antibody, Unconjugated from BioLegend Goat Anti-MLH3 Polyclonal Antibody, Unconjugated from GeneTex Mouse Anti-DNA-PKcs, phospho (Thr2609) Monoclonal Antibody, Unconjugated, Clone 10B1 from BioLegend